Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
1,012 results
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).
- Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: Complete Statistical AnalysisIndependent statistical analysis of Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04538040).
- Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: Complete Statistical AnalysisIndependent statistical analysis of Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BioButton Among Nursing Home Residents: Complete Statistical AnalysisIndependent statistical analysis of BioButton Among Nursing Home Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06665685).
- Bipolar Ventricular Tachycardia (VT) Study: Complete Statistical AnalysisIndependent statistical analysis of Bipolar Ventricular Tachycardia (VT) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02374476).
- Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: Complete Statistical AnalysisIndependent statistical analysis of Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: Complete Statistical AnalysisIndependent statistical analysis of BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00869323).
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- BRANCHIndependent statistical analysis of Bare Metal Bifurcation Stent Clinical Trial in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00607321).
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bridging the Evidence-to-practice Gap: Complete Statistical AnalysisIndependent statistical analysis of Bridging the Evidence-to-practice Gap: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03713515).
- Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): Complete Statistical AnalysisIndependent statistical analysis of BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Busulfan and Cyclophosphamide Followed By ALLO BMT: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Cyclophosphamide Followed By ALLO BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01685411).
- Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): Complete Statistical AnalysisIndependent statistical analysis of Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361140).
- Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01962025).
- C_ASCENTIndependent statistical analysis of Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- C-Pulse IDE Feasibility Study- A Heart Assist System: Complete Statistical AnalysisIndependent statistical analysis of C-Pulse IDE Feasibility Study- A Heart Assist System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00815880).
- C. Difficile and Ursodiol: Complete Statistical AnalysisIndependent statistical analysis of C. Difficile and Ursodiol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02748616).
- Cabergoline in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabergoline in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01730729).
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CACD1Independent statistical analysis of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05283538).
- Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00258960).
- CAFIIndependent statistical analysis of Coil Assisted Flow Diversion Safety and Performance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04187573).
- CairnSurgical Breast Cancer Locator (BCL) Post-Market Study: Complete Statistical AnalysisIndependent statistical analysis of CairnSurgical Breast Cancer Locator (BCL) Post-Market Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06461663).
- CALMextIndependent statistical analysis of CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext): primary endpoint results, effect estimate with confidence interval, sample-size…
- CAMPBELIndependent statistical analysis of CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months): Complete Statistical AnalysisIndependent statistical analysis of Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).
- Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00347438).
- Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…